Up­dat­ed: Verve's land­mark base edit­ing tri­al for car­dio drug runs in­to FDA hold

Four months af­ter kick­ing off the first-ever base edit­ing tri­al in hu­mans, Verve Ther­a­peu­tics is run­ning up against a reg­u­la­to­ry wall.

The FDA placed Verve’s lead pro­gram, VERVE-101, on hold ear­ly Mon­day morn­ing, paus­ing the biotech’s US ef­forts fol­low­ing an IND sub­mis­sion last month. Verve kicked off the Phase Ib tri­al this past sum­mer, dos­ing three pa­tients in New Zealand and the UK start­ing in Ju­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER